Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by GENFIT S.A.

< Previous 1 2 Next >
GENFIT to Present Latest ACLF Research at EASL Congress™ 2024
From GENFIT S.A.
Via GlobeNewswire
GENFIT: May 22, 2024 Combined Shareholders Meeting Results
From GENFIT S.A.
Via GlobeNewswire
GENFIT Reports First Quarter 2024 Financial Information
From GENFIT S.A.
Via GlobeNewswire
GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)
From GENFIT S.A.
Via GlobeNewswire
GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents
From GENFIT S.A.
Via GlobeNewswire
GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F
From GENFIT S.A.
Via GlobeNewswire
GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update
From GENFIT S.A.
Via GlobeNewswire
GENFIT Announces Revenues and Cash Position as of December 31, 2023
From GENFIT S.A.
Via GlobeNewswire
GENFIT Announces 2024 Financial Calendar
From GENFIT S.A.
Via GlobeNewswire
GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)
From GENFIT S.A.
Via GlobeNewswire
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
From GENFIT S.A.
Via GlobeNewswire
GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials
From GENFIT S.A.
Via GlobeNewswire
GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023
From GENFIT S.A.
Via GlobeNewswire
GENFIT: Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine
From GENFIT S.A.
Via GlobeNewswire
GENFIT Reports Third Quarter 2023 Financial Information
From GENFIT S.A.
Via GlobeNewswire
GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023
From GENFIT S.A.
Via GlobeNewswire
GENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technology
From GENFIT S.A.
Via GlobeNewswire
GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update
From GENFIT S.A.
Via GlobeNewswire
GENFIT to Participate in Upcoming Investor Conferences
From GENFIT S.A.
Via GlobeNewswire
GENFIT Announces the Publication of New Data on the Clinical Performance of NIS2+™ in Older Patients in Hepatology Communications
From GENFIT S.A.
Via GlobeNewswire
GENFIT Announces New Data at the European Association for the Study of the Liver (EASL) Congress 2023
From GENFIT S.A.
Via GlobeNewswire
GENFIT Further Strengthens its ACLF Franchise with a Third Clinical-Stage Asset
From GENFIT S.A.
Via GlobeNewswire
GENFIT: May 24, 2023 Combined Shareholders Meeting results
From GENFIT S.A.
Via GlobeNewswire
GENFIT Announces Publication of the Development and Validation of NIS2+™ in the Journal of Hepatology
From GENFIT S.A.
Via GlobeNewswire
GENFIT Reports First Quarter 2023 Financial Information
From GENFIT S.A.
Via GlobeNewswire
GENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week® as part of its ACLF Program
From GENFIT S.A.
Via GlobeNewswire
GENFIT Announces Publication of Extra-Financial Performance Report 2022
From GENFIT S.A.
Via GlobeNewswire
GENFIT Annual Combined General Meeting of May 24, 2023 — Availability of Preparatory Documents
From GENFIT S.A.
Via GlobeNewswire
GENFIT Announces Publication of the 2022 Universal Registration Document and the 2022 Annual Report on Form 20-F
From GENFIT S.A.
Via GlobeNewswire
GENFIT Reports Full-Year 2022 Financial Results and Provides Corporate Update
From GENFIT S.A.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.